Effects of exogenous big endothelin-1 on postischemic cardiac dysfunction and norepinephrine overflow in rat hearts

Hypertension Research

Volumn 34, Issue 2, 2011, Pages 218-224

  Tawa, Masashi ^a,b   Fukumoto, Taiki ^a   Ohkita, Mamoru ^a   Yamashita, Naoto ^a   Geddawy, Ayman ^b   Imamura, Takeshi ^b   Ayajiki, Kazuhide ^b   Okamura, Tomio ^b   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

big endothelin 1; endothelin 1; ischemia reperfusion; norepinephrine

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ATRASENTAN; BIG ENDOTHELIN 1; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME INHIBITOR; NORADRENALIN; SM 19712; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PERFUSION; MALE; NONHUMAN; NORADRENALIN RELEASE; RAT;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; ENDOTHELIN-1; MALE; METALLOENDOPEPTIDASES; MYOCARDIAL REPERFUSION INJURY; NOREPINEPHRINE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SULFONAMIDES; SULFONYLUREA COMPOUNDS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79751501231     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.213     Document Type: Article

References (32)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1998; 332: 411-415.
2. Lü scher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440.
3. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001; 14: 83S-89S. (Pubitemid 32506701)
4. Fujii H, Takiuchi S, Kamide K, Horio T, Niizuma S, Tanaka N, Hashimoto S, Nakatani S, Fukagawa M, Kawano Y. Clinical implications of assessing coronary flow velocity reserve and plasm endothelin-1 in hypertensive patients. Hypertens Res 2005; 28: 911-916. (Pubitemid 43173961)
5. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res 1991; 69: 370-377.
6. Tawa M, Fukumoto T, Ohkita M, Matsumura Y. Role of endogenous endothelin-1 in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts. Eur J Pharmacol 2008; 591: 182-188.
7. Han H, Neubauer S, Braeker B, Ertl G. Endothelin-1 contributes to ischemia/reperfusion injury in isolated rat heart-attenuation of ischemic injury by the endothelin-1 antagonists BQ123 and BQ610. J Mol Cell Cardiol 1995; 27: 761-766.
8. Li XS, Wang QD, Pernow J. Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat. Eur J Pharmacol 1995; 283: 161-168.
9. Illing B, Horn M, Han H, Hahn S, Bureik P, Ertl G, Neubauer S. Protective effect of the specific endothelin-1 antagonist BQ610 on mechanical function and energy metabolism during ischemia/reperfusion injury in isolated perfused rat hearts. J Cardiovasc Pharmacol 1996; 27: 487-494. (Pubitemid 26111069)
10. Yamamoto S, Matsumoto N, Kanazawa M, Fujita M, Takaoka M, Gariepy CE, Yanagisawa M, Matsumura Y. Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts. Circulation 2005; 111: 302-309. (Pubitemid 40165336)
11. Schömig A, Haass M, Richardt G. Catecholamine release and arrhythmias in acute myocardial ischemia. Eur Heart J 1991; 12(suppl F): 38-47.
12. Imamura M, Lander HM, Levi R. Activation of histamine H3 receptors inhibits carriermediated norepinephrine release during protracted myocardial ischemia: comparison with adenosine A1-receptors and a2-adrenoceptors. Circ Res 1996; 78: 475-481.
13. Oikonomidis DL, Tsalikakis DG, Baltogiannis GG, Tzallas AT, Xourgia X, Agelaki MG, Megalou AJ, Fotopoulos A, Papalois A, Kyriakides ZS, Kolettis TM. Endothelin-B receptors and ventricular arrhythmogenesis in the rat model of acute myocardial infarction. Basic Res Cardiol 2010; 105: 235-245.
14. Isaka M, Kudo A, Imamura M, Kawakami H, Yasuda K. Endothelin receptors, localized in sympathetic nerve terminals of the heart, modulate norepinephrine release and reperfusion arrhythmias. Basic Res Cardiol 2007; 102: 154-162. (Pubitemid 46189956)
15. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78: 473-485. (Pubitemid 24250811)
16. Matsumura Y, Hisaki K, Takaoka M, Morimoto S. Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur J Pharmacol 1990; 185: 103-106. (Pubitemid 20254903)
17. Trapani AJ, De Lombaert S, Kuzmich S, Jeng AY. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11. J Cardiovasc Pharmacol 1995; 26: S69-S71.
18. Fecteau MH, Honoré JC, Plante M, Labonté J, Rae GA, D'Orléans-juste P. Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension 2005; 46: 87-92. (Pubitemid 40946496)
19. Grover GJ, Sleph PG, Fox M, Trippodo NC. Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts. J Pharmacol Exp Ther 1992; 263: 1074-1082. (Pubitemid 23157183)
20. Umekawa K, Hasegawa H, Tsutsumi Y, Sato K, Matsumura Y, Ohashi N. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol 2000; 84: 7-15.
21. von Geldern TW, Tasker AS, Sorensen BK, Winn M, Szczepankiewicz BG, Dixon DB, Chiou WJ, Wang L, Wessale JL, Adler A, Marsh KC, Nguyen B, Opgenorth TJ. Pyrrolidine-3-carboxylic acids as endothelin antagonists, 4: side chain conformational restriction leads to ETB selectivity. J Med Chem 1999; 42: 3668-3678. (Pubitemid 29445100)
22. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, Novosad EI, Von Geldern TW, Wessale JL, Winn M, Wu-Wong JR. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276: 473-481. (Pubitemid 126660483)
23. Brunner F, Du Toit EF, Opie LH. Endothelin release during ischemia and reperfusion of isolated perfused rat hearts. J Mol Cell Cardiol 1992; 24: 1291-1305. (Pubitemid 23016052)
24. Sharif I, Kane KA, Wainwright CL. Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic? Cardiovasc Res 1998; 39: 625-632. (Pubitemid 28407595)
25. Pollock DM, Divish BJ, Novosad EI, Burres NS, Opgenorth TJ. In vivo characterization of a phosphoramidon-sensitive endothelin converting enzyme in the rat. Eur J Pharmacol 1993; 231: 459-464. (Pubitemid 23056982)
26. Matsuo G, Matsumura Y, Tadano K, Hashimoto T, Morimoto S. Effects of sarafotoxin S6c on renal haemodynamics and urine formation in anaesthetized dogs. Clin Exp Pharmacol Physiol 1997; 24: 487-491. (Pubitemid 27273824)
27. Tawa M, Fukumoto T, Yamashita N, Ohkita M, Ayajiki K, Okamura T, Matsumura Y. Postconditioning improves post-ischemic cardiac dysfunction independently of norepinephrine overflow after reperfusion in rat hearts: comparison with preconditioning. J Cardiovasc Pharmacol 2010; 55: 6-13.
28. Serneri GG, Cecioni I, Vanni S, Paniccia R, Bandinelli B, Vetere A, Janming X, Bertolozzi I, Boddi M, Lisi GF, Sani G, Modesti PA. Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. Circ Res 2000; 86: 377-385. (Pubitemid 30141755)
29. Khamaisi M, Raz I, Shilo V, Rosenberger C, Dahan R, Abassi Z, Meidan R, Lecht S, Heyman SN. Diabetes and radiocontrast media increase endothelin converting enzyme- .1. in the kidney. Kidney Int 2008; 74: 91-100. (Pubitemid 351841889)
30. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994; 269: 18275-18278. (Pubitemid 24224046)
31. Valdenaire O, Lepailleur-Enouf D, Egidy G, Thouard A, Barret A, Vranckx R, Tougard C, Michel JB. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter. Eur J Biochem 1999; 264: 341-349. (Pubitemid 29424437)
32. Emoto N, Nurhantari Y, Alimsardjono H, Xie J, Yamada T, Yanagisawa M, Matsuo M. Constitutive lysosomal targeting and degradation of bovine endothelin-converting enzyme-1a mediated by novel signals in its alternatively spliced cytoplasmic tail. J Biol Chem 1999; 274: 1509-1518.